Share Price, page-421

Sorry zedcorp - your logic is incorrect. All things being equal if the increase in Neuren's and Acadia's share price are both driven by the same event (positive Ph 3 results), then for every AU$1b additional market cap Acadia is worth Neuren should be worth at least AU$1b increase in market cap - and arguably (as 8horse has pointed out re larger market outside US) AU$3b or more.

It's very hard to come up with any sensible calculation that won't doesn't show every $100m in new revenue/profit Acadia makes long term from Trof will be matched by $300m+ for Neuren (and probably more - they won't have costs...). Long term for every $1 profit Acadia makes from Neuren's drugs Neuren should be making $5-$10.

Either Acadia's increase in market cap is hugely overpriced or Neuren's is hugely underpriced.